Stephen L. Rawlings

Array ( [id] => 12185492 [patent_doc_number] => 20180044428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CANCER THERAPY' [patent_app_type] => utility [patent_app_number] => 15/556864 [patent_app_country] => US [patent_app_date] => 2016-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 18966 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 29 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15556864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11066192 [patent_doc_number] => 20160263155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'T CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/065567 [patent_app_country] => US [patent_app_date] => 2016-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 70850 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15065567 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16548570 [patent_doc_number] => 10881709 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-05 [patent_title] => Immune system modulators and compositions [patent_app_type] => utility [patent_app_number] => 15/555029 [patent_app_country] => US [patent_app_date] => 2016-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 106 [patent_figures_cnt] => 172 [patent_no_of_words] => 117036 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15555029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13430985 [patent_doc_number] => 20180267035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => PROCESSES FOR THE DIAGNOSIS, PROGNOSIS AND MONITORING OF THE PROGRESSION OF CHRONIC LYMPHOID LEUKAEMIA (CLL) AND/OR OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) USING MEMBRANE STIM 1 [patent_app_type] => utility [patent_app_number] => 15/554166 [patent_app_country] => US [patent_app_date] => 2016-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8651 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15554166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13300279 [patent_doc_number] => 20180201676 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => METHODS AND COMPOSITIONS FOR MODULATING LILR PROTEINS [patent_app_type] => utility [patent_app_number] => 15/549995 [patent_app_country] => US [patent_app_date] => 2016-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13552 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15549995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12151556 [patent_doc_number] => 20180022819 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/550143 [patent_app_country] => US [patent_app_date] => 2016-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 42209 [patent_no_of_claims] => 74 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15550143 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12157266 [patent_doc_number] => 20180028531 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'USE OF PLINABULIN IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS' [patent_app_type] => utility [patent_app_number] => 15/550350 [patent_app_country] => US [patent_app_date] => 2016-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 9758 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15550350 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11382904 [patent_doc_number] => 20170008960 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-12 [patent_title] => 'TCR Complex Immunotherapeutics' [patent_app_type] => utility [patent_app_number] => 15/040744 [patent_app_country] => US [patent_app_date] => 2016-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 80 [patent_figures_cnt] => 80 [patent_no_of_words] => 34170 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15040744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16772028 [patent_doc_number] => 10983128 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy [patent_app_type] => utility [patent_app_number] => 15/547304 [patent_app_country] => US [patent_app_date] => 2016-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 18 [patent_no_of_words] => 17850 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15547304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10806541 [patent_doc_number] => 20160152700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'Antigen Binding Proteins Capable of Binding Thymic Stromal Lymphopoietin' [patent_app_type] => utility [patent_app_number] => 15/014828 [patent_app_country] => US [patent_app_date] => 2016-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 33232 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15014828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10799195 [patent_doc_number] => 20160145351 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-26 [patent_title] => 'HUMAN ANTIGEN BINDING PROTEINS THAT BIND BETA-KLOTHO, FGF RECEPTORS AND COMPLEXES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/012939 [patent_app_country] => US [patent_app_date] => 2016-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 62040 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15012939 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10799181 [patent_doc_number] => 20160145338 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-26 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR CD22' [patent_app_type] => utility [patent_app_number] => 15/012023 [patent_app_country] => US [patent_app_date] => 2016-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 23302 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15012023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12158871 [patent_doc_number] => 20180030136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'ICOS BINDING PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/546369 [patent_app_country] => US [patent_app_date] => 2016-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 51266 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15546369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12126310 [patent_doc_number] => 20180009895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-11 [patent_title] => 'ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (SCCARS) FOR CANCER IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 15/546633 [patent_app_country] => US [patent_app_date] => 2016-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 42726 [patent_no_of_claims] => 66 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15546633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12118841 [patent_doc_number] => 20180002427 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'CLL1-SPECIFIC MULTI-CHAIN CHIMERIC ANTIGEN RECEPTOR' [patent_app_type] => utility [patent_app_number] => 15/546619 [patent_app_country] => US [patent_app_date] => 2016-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 34906 [patent_no_of_claims] => 66 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15546619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10791567 [patent_doc_number] => 20160137723 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-19 [patent_title] => 'MONOCLONAL ANTIBODIES THAT REACT WITH THE CAPSULE OF BACILLUS ANTHRACIS' [patent_app_type] => utility [patent_app_number] => 15/003719 [patent_app_country] => US [patent_app_date] => 2016-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 25471 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15003719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12769936 [patent_doc_number] => 20180148480 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => SYNTHETIC ENHANCEMENT OF THE T-CELL ARMAMENTARIUM AS AN ANTI-CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 15/544156 [patent_app_country] => US [patent_app_date] => 2016-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14965 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15544156 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10822093 [patent_doc_number] => 20160168257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-16 [patent_title] => 'MOLECULES THAT BIND CD180, COMPOSITIONS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/993917 [patent_app_country] => US [patent_app_date] => 2016-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 18652 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14993917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11067707 [patent_doc_number] => 20160264671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'BISPECIFIC SINGLE CHAIN ANTIBODIES WITH SPECIFICITY FOR HIGH MOLECULAR WEIGHT TARGET ANTIGENS' [patent_app_type] => utility [patent_app_number] => 14/991189 [patent_app_country] => US [patent_app_date] => 2016-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 73843 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14991189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11067716 [patent_doc_number] => 20160264679 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'ANTI-ERBB3 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/987374 [patent_app_country] => US [patent_app_date] => 2016-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 33285 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14987374 [rel_patent_id] =>[rel_patent_doc_number] =>)